Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation-Reference-Cited by-同舟云学术

Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation

Published:2021-09-24 Issue:38 Volume:100 Page:e27082
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Mahn Robert,Sadeghlar Farsaneh,Bartels Alexandra,Zhou Taotao,Weismüller Tobias,Kupczyk Patrick,Meyer Carsten,Gaertner Florian C.,Toma Marieta,Vilz Tim,Knipper Petra,Glowka Tim,Manekeller Steffen,Kalff Jörg,Strassburg Christian P.,Gonzalez-Carmona Maria A.

Funder

Deutsche Krebshilfe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference36 articles.

1. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma;J Hepatol,2018

2. Hepatocellular cancer in the non-cirrhotic liver;Alkofer;J Visc Surg,2011

3. Hepatocellular carcinoma in the noncirrhotic liver;Gaddikeri;Am J Roentgenol,2014

4. Strategies for safer liver surgery and partial liver transplantation;Clavien;N Engl J Med,2007

5. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis;Lang;Br J Surg,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for hepatocellular carcinoma in liver transplant patients (Literature review);Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH);2023-09-12

2. An Inflammation-Associated Prognosis Model for Hepatocellular Carcinoma Based on Adenylate Uridylate- (AU-) Rich Element Genes;Mediators of Inflammation;2023-05-02

3. Recent advances in recurrent hepatocellular carcinoma therapy;World Journal of Hepatology;2023-04-27

4. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2023-01-15

5. Cabozantinib/sorafenib;Reactions Weekly;2022-02